From ‘Genesis’ to Reality: Decoding the AI Revolution
Co-Author Craig Mundie and ISB’s Dr. Jim Heath discuss AI’s rapid evolution, ethical considerations, and potential to revolutionize science and society in a compelling Town Hall event.
News
Melanoma Starts Evading Treatment Within Hours – Here’s How to Stop It
ISB researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.
More News (Optimizing Outcomes)
Improving Cancer Care for All: A Conversation with Drs. Jim Heath, Jim Allison and Lynda Chin
ISB President Dr. Jim Heath talks with Nobel laureate and Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center Dr. Jim Allison and Apricity Health CEO Dr. Lynda Chin. Drs. Heath, Allison and Chin discuss disparities in cancer care and ways to bring state-of-the-art care from big cities and major academic centers to rural and underserved areas.
ISB Leading NCI Comprehensive Cancer Center to Study Sequential Targeted Inhibitors and Immunotherapies
The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.
Looking at Tumors Through a New Lens: New Research May Improve Efficacy of Glioblastoma Immunotherapy
To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.